Argus upgrades Regeneron stock to Buy with USD 850 target

Published on 10/01/2026 at 15:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock trades at EUR 677.95 on October 1, 2026 after EUR 669.25, plus 1.30 percent. Q2 revenue rose 17.00 percent to USD 4.29 billion.

Fotorealistisches Biotech-Labor mit Forschern und Pipetten an sterilen Arbeitsplätzen — Regeneron Pharma US75886F1075 zeigt ein fotorealistisches Biotech-Labor mit Forschern bei sorgfältigen Pipettierarbeiten am sterilen Steriltisch, Illustration mit AI erstellt.

Regeneron (ISIN US75886F1075) was trading at EUR 677.95 at Lang & Schwarz on October 1, 2026 at 3:21 p.m. CEST, up 1.30 percent from the prior close of EUR 669.25. According to Investing.com on October 1, 2026, Argus upgraded Regeneron to Buy from Hold and set a USD 850.00 price target.

Argus points to Dupixent growth

The analyst change centers on Dupixent, whose sales rose 38.00 percent year over year to USD 6.00 billion in the second quarter of 2026, according to Investing.com. The figure refers to global sales for the medicine, which Regeneron markets with Sanofi, rather than Regeneron's consolidated revenue alone.

Regeneron's total revenue reached USD 4.29 billion in the second quarter of 2026, an increase of 17.00 percent from the prior-year period. The company also reported non-GAAP earnings of USD 14.29 per share for that quarter, according to Investing.com.

Revenue growth meets pipeline risks

The operating picture is mixed across the portfolio. Libtayo and Praluent sales grew 30.00 percent and 20.00 percent, respectively, in the second quarter of 2026, while the Eylea franchise declined, according to Investing.com. That split leaves Dupixent and Eylea HD central to the earnings story as the company manages concentration in its largest products.

Argus also cited the potential for Regeneron's cemdisiran program, which has a Food and Drug Administration target action date in November 2026. The analyst estimated peak annual sales potential of USD 1.50 billion to USD 2.50 billion if the medicine is approved, while the USD 850.00 target implies a higher valuation than the current Nasdaq quote.

Next results date is October 30

Regeneron will report third-quarter 2026 financial and operating results on October 30, 2026, according to the company's investor information page at Regeneron. The date gives investors a defined checkpoint for Dupixent momentum, Eylea HD performance and the effect of pipeline developments.

Stock remains below its yearly high

On the Nasdaq, REGN was last at USD 758.27 on September 30, 2026 at 4:00 p.m. ET. Its 52-week range was USD 541.00 to USD 859.34, while market capitalization stood at USD 78.1 billion on the same date.

The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.